FDA Premarket Activity Safe From Current Political Storm – Ex Chief Counsel
This article was originally published in The Gray Sheet
Executive Summary
Current public pressure on the FDA in the wake of a string of high-profile safety problems for both drugs and devices will not make the agency more restrained in approving premarket applications, according to one former top FDA official